Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Released May 16, 2022, after the close
10-Q filed May 16, 2022, 46 days after period end · 0001654954-22-006980
Q1 2022 · 10-Q
Revenue—
Net Income-$2.72M-$2.72MN/M vs Q1 2021N/M vs Q4 2021 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Operating Income$2,718,639−88.6% Operating Cash Flow-$2,937,677N/M Free Cash Flowderived-$2,944,000N/M Filing lag
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end